SCHEMBL2175855

SCHEMBL2175855

CC(=O)OC[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)OC(C)=O

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.96
ABCB1 P08183 1/20 0.48
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
TSHR P16473 2/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TRPV1 Q8NER1 1/20 0.36
PGD P52209 1/20 0.35
CHRM2 P08172 2/20 0.34
CHRM4 P08173 2/20 0.34
CHRM1 P11229 2/20 0.34
TBXA2R P21731 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 1/20 0.33
GALR3 O60755 1/20 0.33
MAPT P10636 1/20 0.33
BLM P54132 1/20 0.33
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150717 1.00 TDP1 (0.96) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL270042 1.00 TDP1 (0.96) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL13168216 1.00 TDP1 (0.96) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL7152317 1.00 TDP1 (0.96) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL7149374 1.00 TDP1 (0.96) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL826717 1.00 TDP1 (0.96) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL2956081 0.98 TDP1 (1.00) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL2956079 0.98 TDP1 (1.00) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL7154355 0.95 TDP1 (0.88) TDP1ABCB1POLBMAPK1TSHR
SCHEMBL7146329 0.95 TDP1 (0.88) TDP1ABCB1POLBMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591416-B2 Exopolysaccharides and uses thereof SOFAR S.P.A. (IT) 2023-02-28 US claimed
US-20190345268-A1 EXOPOLYSACCHARIDES AND USES THEREOF ALFASIGMA S.P.A. (IT) 2019-11-14 US claimed
CN-110191957-B Exopolysaccharides and uses thereof 索发股份公司 2023-07-28 CN disclosed
US-11591416-B2 Exopolysaccharides and uses thereof SOFAR S.P.A. (IT) 2023-02-28 US disclosed
US-20190345268-A1 EXOPOLYSACCHARIDES AND USES THEREOF ALFASIGMA S.P.A. (IT) 2019-11-14 US disclosed
US-9180084-B2 Cassia derivatives LUBRIZOL ADVANCED MATERIALS, INC. (US) 2015-11-10 US disclosed
EP-2717844-B1 CASSIA DERIVATIVES LUBRIZOL ADVANCED MAT INC (US) 2015-07-08 EP disclosed
US-9062131-B2 Cassia derivatives LUBRIZOL ADVANCED MATERIALS, INC. (US) 2015-06-23 US disclosed
EP-2563818-B1 CASSIA DERIVATIVES LUBRIZOL ADVANCED MAT INC (US) 2014-12-17 EP disclosed
EP-2513151-B1 CASSIA DERIVATIVES LUBRIZOL ADVANCED MAT INC (US) 2014-09-10 EP disclosed
US-20140127149-A1 Cassia Derivatives LUBRIZOL ADVANCED MATERIALS, INC. (US) 2014-05-08 US disclosed
US-20130129639-A1 Cassia Derivatives LUBRIZOL ADVANCED MATERIALS, INC. (US) 2013-05-23 US disclosed
EP-2563818-A1 CASSIA DERIVATIVES Lubrizol Advanced Materials, Inc. (US) 2013-03-06 EP disclosed
US-20130034505-A1 Cassia Derivatives LUBRIZOL ADVANCED MATERIALS, INC. (US) 2013-02-07 US disclosed
WO-2012170171-A1 CASSIA DERIVATIVES LUBRIZOL ADVANCED MATERIALS, INC. (US) 2012-12-13 WO disclosed
EP-2513151-A1 CASSIA DERIVATIVES Lubrizol Advanced Materials, Inc. (US) 2012-10-24 EP disclosed
WO-2011137218-A1 CASSIA DERIVATIVES LUBRIZOL ADVANCED MATERIALS, INC. (US) 2011-11-03 WO disclosed
WO-2011081907-A1 CASSIA DERIVATIVES LUBRIZOL ADVANCED MATERIALS, INC. (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129639-A1 Cassia Derivatives MAN1B1, SIGLEC7, MAN2B2 TDP1 2786/4885ABCB1 4337/4885POLB 4613/4885
US-20140127149-A1 Cassia Derivatives MAN1B1, SIGLEC7, MAN2B2 TDP1 2868/4885ABCB1 4195/4885POLB 4528/4885
US-11591416-B2 Exopolysaccharides and uses thereof TLR5, TLR3, TLR2 TDP1 3938/4885ABCB1 4419/4885POLB 4212/4885
US-20130034505-A1 Cassia Derivatives SIGLEC7, MAN1B1, FUT4 TDP1 2742/4885ABCB1 4386/4885POLB 4582/4885
US-20190345268-A1 EXOPOLYSACCHARIDES AND USES THEREOF TLR5, TLR3, TLR2 TDP1 3938/4885ABCB1 4419/4885POLB 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.